Bristol Myers to Move BMS-986278 Into Phase 3 For Idiopathic

By Colin Kellaher


Bristol Myers Squibb on Monday said data from a Phase 2 study of BMS-986278 in idiopathic pulmonary fibrosis support advancement of the drug candidate into Phase 3 trials.

... | May 22, 2023

Related Keywords

New York , United States , Bristol Myers Squibb , Colin Kellaher , Bristol Myers , , Myers Squibb , Dow Jones , Bristol Myers Squibb Company Stock Exchange , News , Information , Press Release , Y , Colin , Kellaher , Bristol , Myers , Squibb , N , Monday , Aid , Data , Rom , Hase , Study , F , Idiopathic , Pulmonary , Ibrosis , Support , Advancement , The , Drug , Candidate , Into , Y Bmy Us1101221083 ,